RU EN
Get tested

About us

The CA-62 test was developed and is manufactured by JVS Diagnostics LLC, a biotechnology research and manufacturing company and the owner of this website. In Russia, testing is performed by the authorized clinical laboratory ONCODIAG; in North America, by a CLIA-certified laboratory in Montreal.

Companies

JVS Diagnostics

Developer and manufacturer of the CA-62 test system — the first test of its kind for early detection of epithelial malignancies. Operating since 2018.

Its research laboratory and in vitro diagnostic manufacturing site are located at the Skolkovo Technopark.

The team includes MDs and PhDs in medicine, chemistry and pharmaceutical sciences. Manufacturer and registration holder of the test system, owner of ca-62.com.

Legal name
JVS Diagnostics LLC (ООО «Джейвис Диагностикс»)
OGRN
5177746399837
INN
7731395117
Skolkovo participant
No. 1122048

ONCODIAG

Authorized clinical diagnostic laboratory where CA-62 testing is performed in Russia; works with laboratory networks and partner clinics.

Legal name
ONCODIAG LLC (ООО «Онкодиаг»)
OGRN
1207700505209
Medical licence
No. Л041-01137-77/00632300
Skolkovo participant
No. 1124262

Intellectual property

The CA-62 antigen, the method for its detection and the reagent kit are protected by patents.

NumberTypeTitle
RU 2818471Patent (Russia)Novel cancer antigen for early cancer detection, methods for its production, isolation and detection
RU 2735918Patent (Russia)Reagent kit for detecting a marker of epithelial carcinomas
RU 2025110811Patent applicationMonoclonal antibodies to the CA-62 cancer antigen, methods for their production, purification and use

Regulatory and legal information

Clinical publications are listed in the physicians section.

North America
Laboratory-developed test (LDT) since 2025, performed by a CLIA-certified laboratory in Montreal, Canada. LDTs are not cleared or approved by the U.S. FDA.
Website owner
JVS Diagnostics LLC, OGRN 5177746399837
Russia
Roszdravnadzor registration certificate No. RZN 2020/9880 of 3 April 2020; holder — JVS Diagnostics LLC. CA-62 is the world’s first multi-cancer (MCED) test system for detecting epithelial carcinomas with no restriction on tumour site to be authorised for use by a government authority. Carcinomas account for about 90% of all cancers. For comparison: Galleri (GRAIL, USA) has been offered commercially since June 2021 as a laboratory-developed test, without FDA approval.
Copyright
Texts, diagrams and materials on this site belong to their respective rights holders. Please cite ca-62.com when quoting.
Medical information
Information on this site is for reference only and does not replace a consultation with a physician. Test results are interpreted by a physician.
Reference tools for physicians
Reference information for healthcare professionals only; opens after confirming professional status. Not intended for diagnosis or clinical decision-making; entered data are not stored.